KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Bradycardia and Other Arrhythmias in Patients With Hepatorenal Syndrome-Acute Kidney Injury Following Terlipressin Treatment: A Pooled Analysis of Three North American Phase III Clinical Studies.

Jasmohan S Bajaj, Paul Kwo, Stephen Chris Pappas, Jacqueline G O'Leary, Khurram Jamil, Sanaz Cardoza, Florence Wong

Aliment Pharmacol Ther 62(11-12) 1192-1201

PMID40704461
PMCIDPMC12646624
DOI10.1111/apt.70297
发表日期2025-07-24
入排依据:未发现恶性肿瘤人群证据。
已检查 4 张 PMC Figure,均未识别为 KM 图:FIGURE 1:研究设计图;FIGURE 2:AI 判定为 other;FIGURE 3:AI 判定为 other;FIGURE 4:AI 判定为 forest plot。
摘要

摘要

BACKGROUND: Terlipressin is the FDA-approved systemic vasoconstrictor therapy for hepatorenal syndrome-acute kidney injury (HRS-AKI)-a rapidly progressive renal failure occurring in patients with decompensated cirrhosis and ascites. Bradycardia, a known effect of terlipressin, as well as other arrhythmias, has previously been reported in terlipressin-treated patients. AIM: To assess terlipressin-related cardiac adverse events (AEs) in patients with HRS-AKI. METHODS: Three North American-centric Phase III, randomised, placebo-controlled studies (OT-0401, REVERSE, CONFIRM) were pooled in the largest-to-date prospective database. Cardiac AEs were reported by the investigators for each trial and retrospectively analysed. RESULTS: Bradycardia was the only cardiac AE reported more frequently in terlipressin-treated patients compared with placebo (6.3% [22/349] vs. 0.8% [2/249]). In the terlipressin group, no bradycardia AEs were serious, 4.5% (1/22) of patients required a dose interruption, 9.1% (2/22) required a dose reduction, and none discontinued treatment due to bradycardia. The incidences of other arrhythmia AEs were similar in both treatment groups (terlipressin: 7.4% [26/349]; placebo 8.8% [22/249]). The incidence of atrial fibrillation serious AEs (SAEs) was low (terlipressin: 0.9% [3/349]; placebo: 1.6% [4/249]). There were no AE reports of torsades de pointes, while a QT interval prolongation was reported in two patients. CONCLUSIONS: In a pooled analysis, bradycardia was observed in 6% of terlipressin-treated patients but rarely required a dose interruption or reduction. Arrhythmia SAE incidences were low and similar in both treatment groups. Routine intensive cardiac monitoring for the detection of arrhythmias may not be necessary during terlipressin administration. TRIAL REGISTRATION: OT-0401: NCT00089570, REVERSE: NCT01143246 and CONFIRM: NCT02770716.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1Study design. Based on references [ 1 , 10 , 12 ]. ‡ Concomitant albumin was strongly recommended at a dose of 100 g on Day 1 and then 25 g/day until the EOT in OT‐0401; in CONFIRM and REVERSE, the recommended albumin dose was 1 g/kg to a maximum of 100 g on Day 1 and 20–40 g/day thereafter. § If, after Day 3, SCr levels had decreased—but by < 30%—then the terlipressin dose could be increased to 2 mg Q6H. AKI, acute kidney injury; EOT, end of treatment; HRS, hepatorenal syndrome; IV, intravenous; SCr, serum creatinine.
非 KM Figure
FIGURE 2Incidence of bradycardia, atrial fibrillation and ventricular tachycardia AEs in each treatment group; pooled safety population. AE, adverse event.
非 KM Figure
FIGURE 3Bradycardia‐related outcomes; pooled safety population.
非 KM Figure
FIGURE 4Association of baseline characteristics with bradycardia; terlipressin‐treated patients in the pooled safety population. p values were derived from a univariate logistic regression analysis. AAH, alcohol‐associated hepatitis; ACLF, acute‐on‐chronic liver failure; INR, international normalised ratio; MAP, mean arterial pressure; MELD, Model for End‐Stage Liver Disease; OR, odds ratio; SCr, serum creatinine; SIRS, systemic inflammatory response syndrome.
非 KM Figure